Breast Cancer Clinical Trial
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug.
PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.
Full Description
OBJECTIVES:
Determine the maximum tolerated dose of motexafin gadolinium and doxorubicin in patients with advanced malignancies.
Determine the dose-limiting toxicity of this regimen in these patients.
Determine the safety and tolerability of this regimen in these patients.
Determine the pharmacokinetics of this regimen in these patients.
Evaluate the tumor response in patients treated with this regimen.
OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to 1 of 2 groups.
Group A:
Course 1: Patients receive motexafin gadolinium IV over 30 minutes on days 1, 8, 9, and 10 and doxorubicin IV over 15 minutes on day 8.
Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over 15 minutes.
Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin IV over 15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3. Treatment repeats every 21 days.
Group B:
Course 1: Patients receive motexafin gadolinium IV over 30 minutes on day 1 and doxorubicin IV over 15 minutes on day 8.
Course 2: 28 days after the beginning of course 1, patients receive doxorubicin IV over 15 minutes on day 1 and motexafin gadolinium IV over 30 minutes on days 1-3.
Courses 3-6: Beginning 21 days after course 2, patients receive doxorubicin and motexafin gadolinium as in group A.
Treatment in both groups continues for up to 6 courses in the absence of disease progression, unacceptable toxicity, or a cumulative doxorubicin dose of 450 mg/m^2.
Cohorts of 3-6 patients receive escalating doses of doxorubicin and motexafin gadolinium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which no more than 0 of 3 or 1 of 6 patients experience dose-limiting toxicity.
Patients are followed at 1 and 2 months.
PROJECTED ACCRUAL: A total of 3-48 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed advanced malignancy that is considered incurable
Recurrent or metastatic disease
Relapsed solid tumors include, but are not limited to the following sites:
Lung
Breast
Colon
Prostate
Head and neck
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age:
18 and over
Sex
Not specified
Menopausal status
Not specified
Performance status:
ECOG 0-2
Life expectancy:
Not specified
Hematopoietic:
Absolute neutrophil count at least 1,500/mm^3
Platelet count at least 100,000/mm^3
Hepatic:
Bilirubin no greater than 1.5 mg/dL
AST and ALT no greater than 2 times upper limit of normal
Renal:
Creatinine no greater than 2.0 mg/dL
Cardiovascular:
LVEF greater than 45% at rest
No prior myocardial infarction
No congestive heart failure
No clinically significant ventricular arrhythmias
Other:
No history of HIV infection
No history of porphyria
No glucose-6-phosphate dehydrogenase deficiency
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for at least 6 months after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
At least 28 days since prior chemotherapy
No prior lifetime cumulative doxorubicin exposure of more than 300 mg/m^2
No other concurrent cytotoxic chemotherapy
Endocrine therapy:
Not specified
Radiotherapy:
At least 28 days since prior radiotherapy
No concurrent radiotherapy
Surgery:
No concurrent surgery
Other:
At least 14 days since prior multidrug resistance-modulating drugs (e.g., PSC833 or cyclosporine)
No other concurrent antineoplastic or investigational agents
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.